Public Health Implications of Recent Clinical Evidence on Omega-3 Fatty Acids and Cardiovascular Disease, Part 2
Tuesday, June 23, 2020
2:00 PM– 3:30 PM (EDT)
Sponsored by Royal DSM
CPE credit is no longer available to be claimed for this webinar.
Click here for more information about other continuing education opportunities available from ASN.
Equivocal results in some recent clinical trials have created confusion about the role of omega-3 fatty acids in cardiovascular health. The publication of three large trials (ASCEND, REDUCE-IT and VITAL) between 2018 and 2019 has significantly increased the evaluable body of clinical evidence, and a recent meta-analysis of large supplementation trials has reported that EPA and DHA positively impacted several important cardiovascular outcomes in a dose-response manner. Several authoritative statements have been issued by regulatory agencies and scientific societies prior to this new information. In this session, we will explore the public health implications of these new findings and discuss what needs to be considered as the totality of the evidence is evaluated in terms of the new expanded Dietary Reference Intakes model.
CHAIR
Penny Kris-Etherton, PhD, RD, FAHA, FNLA, FASN, CLS
Distinguished Professor of Nutrition, The Pennsylvania State University, University Park, Pennsylvania
SPEAKERS
Ann Skulas-Ray, PhD
Assistant Professor, Department of Nutritional Sciences, University of Arizona
Patsy Brannon, PhD, RD
Professor, Department of Nutrition, Cornell University